BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, January 13, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Other news to note for Sept. 14, 2022

Sep. 14, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Apollomics, Arctic, Biomarin, Biphytis, Caladrius, Cend, Coave, CSL, Eton, Foundation, Medincell, Metis, Nacuity, Obseva, Radiopharm, Relay, Respira, Sabin, Sunstone, Valeo.
Read More

In the clinic for Sept. 14, 2022

Sep. 14, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adamis, Akero, Amolyt, Bioatla, Eli Lilly, Lyra, Nanoscope, On Target, Oramed, Rayzebio, Recursion Selection Sonalasense, Vaxxinity.
Read More
Microscope and coronavirus illustration
Infection

Tikomed reports in vitro findings on ILB against coronavirus infection

Sep. 14, 2022
Tikomed AB has reported an in vitro study evaluating the antiviral effect of its lead drug candidate ILB in coronavirus infection.
Read More

Regulatory actions for Sept. 13, 2022

Sep. 13, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Acadia, Biolinerx, BMS, Chiesi, Mersana, Vaxxinity.
Read More
Infection

Invivyd's NVD-200 shows in vitro neutralizing activity against SARS-CoV-2 omicron variants

Sep. 13, 2022
Invivyd Inc. (formerly Adagio Therapeutics Inc.) has generated multiple next-generation candidate antibodies for the prevention and treatment of COVID-19, including two molecules designated for near-term clinical development in combination as NVD-200.
Read More
Antibodies block virus from cell
Infection

SP1-77, a novel broad and potent antibody neutralizing all SARS-CoV-2 variants

Sep. 13, 2022
Researchers from Boston Children’s Hospital and Harvard Medical School reported the discovery and preclinical evaluation of SP1-77, a novel humanized monoclonal IgG-κ antibody targeting the receptor-binding-domain (RBD) of spike (S) glycoprotein of all SARS-CoV-2 variants.
Read More

Other news to note for Sept. 12, 2022

Sep. 12, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adagio, Adial, Alume, Aptose, Attralus, Azura, Bavarian Nordic, Celgren, Cellusion, Epivax, Fosun, Infexious, Intravacc, Invivyd, Purnovate.
Read More
Infection

Avacc 10 for SARS-CoV-2 reduces upper respiratory tract viral load in preclinical studies

Sep. 12, 2022
Intravacc BV has announced additional preclinical and toxicology data for Avacc 10, the company's SARS-CoV-2 intranasal candidate vaccine, showing a reduction in upper respiratory tract viral load, broad cross protection against circulating variants of concern and a promising safety profile.
Read More
Japanese shield and coronavirus

Japanese researchers develop COVID-19 and cancer detecting sensor

Sep. 9, 2022
By David Ho
A team of researchers at Toyohashi University of Technology in Japan have come up with a semiconductor sensor that can detect minute traces of biomarkers for infections or diseases.
Read More

Regulatory actions for Sept. 9, 2022

Sep. 9, 2022
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amylyx, Neuroplast, Revance, Silence, Vanda, Veru, Yishengbio.
Read More
Previous 1 2 … 79 80 81 82 83 84 85 86 87 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 12, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 12, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • Icons representing scientific research

    Science in 2025: the best of the rest

    BioWorld Science
    A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
  • Lung cancer illustration

    LINC01116 has prognostic value in lung cancer, study shows

    BioWorld MedTech
    Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing